Estados financieros detallados de Compass Therapeutics, Inc. (CMPX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.83, CMPX presenta beneficios negativos (P/E no significativo) y un ROE del -38.71%. La capitalización bursátil es de $330M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | $850000 | 0 |
| Coste de Ventas | $1.9M | 0 | 0 | 0 | 0 | 0 | 0 | $1.5M |
| Beneficio Bruto | -$1.9M | 0 | 0 | 0 | 0 | 0 | $850000 | -$1.5M |
| I+D | $27.1M | $22.4M | $14.9M | $20.3M | $30.0M | $38.1M | $42.3M | $56.0M |
| Generales y Administrativos | $11.2M | $11.6M | $12.9M | $10.9M | $11.7M | $12.2M | $15.1M | $16.9M |
| Gastos Operativos | $38.3M | $34.1M | $27.8M | $81.9M | $41.7M | $50.4M | $57.5M | $71.4M |
| Beneficio Operativo | -$38.3M | -$34.1M | -$27.8M | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M |
| EBITDA | -$35.7M | -$31.9M | -$25.4M | -$80.2M | -$35.0M | -$40.6M | -$47.6M | -$65.0M |
| Gastos por Intereses | $767000 | $1.2M | $908000 | $370000 | $2.4M | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$38.2M | -$34.7M | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| Impuestos | $103000 | $91000 | $32000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$38.3M | -$34.7M | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| BPA | $-7.66 | $-0.67 | $-0.52 | $-1.31 | $-0.35 | $-0.33 | $-0.36 | $-0.42 |
| BPA Diluido | $-7.66 | $-0.67 | $-0.52 | $-1.31 | $-0.35 | $-0.33 | $-0.36 | $-0.42 |
| Acciones en Circulación (Diluidas) | $5.0M | $52.1M | $56.2M | $62.9M | $105.2M | $127.0M | $137.1M | $157.7M |
Balance (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $57.5M | $25.3M | $47.1M | $144.5M | $34.9M | $24.2M | $43.5M | $30.6M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | $151.7M | $128.2M | $83.2M | $178.3M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $58.9M | $26.2M | $50.2M | $147.1M | $194.8M | $153.9M | $132.8M | $209.8M |
| Inmovilizado Material | $5.4M | $3.8M | $1.1M | $6.3M | $4.5M | $2.7M | $7.1M | $9.2M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $64.6M | $30.4M | $51.9M | $153.8M | $199.6M | $156.9M | $140.4M | $219.6M |
| Cuentas por Pagar | $1.7M | $629000 | $1.1M | $867000 | $3.4M | $4.1M | $2.2M | $1.6M |
| Deuda a Corto | $3.7M | $5.6M | $7.5M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $8.5M | $9.8M | $10.1M | $10.6M | $16.2M | $7.8M | $8.9M | $14.0M |
| Deuda a Largo | $11.1M | $9.3M | $1.9M | 0 | 0 | 0 | 0 | $8.8M |
| Pasivos Totales | $149.4M | $149.0M | $12.0M | $13.7M | $18.0M | $8.3M | $15.2M | $22.8M |
| Reservas | -$87.2M | -$121.9M | -$151.4M | -$233.6M | -$272.8M | -$315.3M | -$364.7M | -$431.2M |
| Patrimonio Neto | -$84.8M | -$118.6M | $39.9M | $140.1M | $181.6M | $148.5M | $125.2M | $196.8M |
| Deuda Total | $14.8M | $14.9M | $9.3M | $4.0M | $2.9M | $1.7M | $6.6M | $9.8M |
| Deuda Neta | -$42.8M | -$10.4M | -$37.7M | -$140.5M | -$183.7M | -$150.7M | -$120.1M | -$199.1M |
| Capital Circulante | $50.4M | $16.4M | $40.1M | $136.5M | $178.6M | $146.1M | $123.9M | $195.9M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$38.3M | -$34.7M | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| Amortizaciones | $1.9M | $2.1M | $2.4M | $1.6M | $1.9M | $1.9M | $1.8M | -$1.4M |
| Compensación en Acciones | $656000 | $915000 | $4.0M | $4.0M | $5.3M | $6.1M | $8.6M | $8.4M |
| Cambio en Capital Circulante | $2.2M | -$257000 | -$3.6M | $6.2M | -$1.3M | -$2.9M | -$4.1M | $9.2M |
| Flujo de Caja Operativo | -$33.7M | -$31.7M | -$26.8M | -$19.7M | -$34.1M | -$40.6M | -$44.9M | -$49.1M |
| Inversiones (CapEx) | -$2.0M | -$466000 | -$106000 | -$1.6M | -$212000 | -$30000 | -$44000 | -$25000 |
| Adquisiciones | 0 | 0 | $144000 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$35.7M | -$32.2M | -$26.9M | -$21.2M | -$34.3M | -$40.6M | -$44.9M | -$49.2M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -100.0% | |||||||
| Crecimiento Beneficio Neto (anual) | +9.3% | +15.1% | -178.6% | +52.3% | -8.3% | -16.2% | -34.7% | |
| Crecimiento BPA (anual) | +91.3% | +22.4% | -151.9% | +73.3% | +5.7% | -9.1% | -16.7% | |
| Cambio en Acciones (anual) | +942.2% | +7.9% | +11.8% | +67.3% | +20.8% | +7.9% | +15.0% | |
| Crecimiento FCF (anual) | +9.8% | +16.4% | +21.1% | -61.7% | -18.4% | -10.5% | -9.5% | |
| Margen Bruto | 100.0% | |||||||
| Margen Operativo | -6661.8% | |||||||
| Margen EBITDA | -5602.6% | |||||||
| Margen Neto | -5808.8% | |||||||
| Margen FCF | -5282.2% | |||||||
| Tasa Impositiva Efectiva | -0.3% | -0.3% | -0.1% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-7.14 | $-0.62 | $-0.48 | $-0.34 | $-0.33 | $-0.32 | $-0.33 | $-0.31 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $5.0M | $52.1M | $56.2M | $62.9M | $105.2M | $127.0M | $137.1M | $157.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -38.71% |
| Rentabilidad sobre capital invertido | -46.15% |
| Rentabilidad sobre activos | -38.62% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.06 |
| Ratio corriente | 11.22 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -1.11 | -12.69 | -16.35 | -2.42 | -14.37 | -4.73 | -4.03 | -12.79 |
| P/VC | -0.50 | -3.73 | 11.96 | 1.42 | 2.91 | 1.33 | 1.59 | 4.30 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 233.89 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -6661.8% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5808.8% | 0.0% |
Empresas relacionadas: BCYC · CRVS · FDMT · FULC · GOSS · KALV · LXRX
Explorar sector: Healthcare · Biotechnology
Más secciones de CMPX: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones